U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H32N2O11P2
Molecular Weight 514.401
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NU-3

SMILES

CCCCOP(O)(=O)OC[C@H]1O[C@H](C[C@@H]1OP(O)(=O)OCCCC)N2C=C(C)C(=O)NC2=O

InChI

InChIKey=ZXQBUNYVGNOEBQ-ARFHVFGLSA-N
InChI=1S/C18H32N2O11P2/c1-4-6-8-27-32(23,24)29-12-15-14(31-33(25,26)28-9-7-5-2)10-16(30-15)20-11-13(3)17(21)19-18(20)22/h11,14-16H,4-10,12H2,1-3H3,(H,23,24)(H,25,26)(H,19,21,22)/t14-,15+,16+/m0/s1

HIDE SMILES / InChI
1-(3,5-BIS-O-(BUTOXYHYDROXYPHOSPHINYL)-2-DEOXY-D-ERYTHRO-PENTOFURANOSYL)-5-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE (Nu-3), a Bisphosphocins, is being developed by Lakewood-Amedex (formerly Nu Pharmas), for the treatment of diabetic foot ulcer, lung infections, stomatitis. Nu-3, a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria, recently completed a Phase 1/2a clinical trial in patients, showing no treatment-related adverse events and a trend toward efficacy. Patients treated with 2% Nu-3 for seven days had a 65.5% reduction in ulcer area versus a 29.9% reduction in the placebo arm, as measured 14 days after treatment began. In addition, 62.5% of patients treated with 2% Nu-3 saw a reduction in the microbiological load, versus 20% in the placebo. Three additional Phase 2a adaptive arm clinical trials providing robust clinical data in areas of urgent medical need are expected to be completed by 2020.

Approval Year

PubMed

PubMed

TitleDatePubMed
Acute, multiple-dose dermal and genetic toxicity of Nu-3: a novel antimicrobial agent.
2010
Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide.
2011 Jan 14

Sample Use Guides

Patients treated with 2% Nu-3 for seven days had a 65.5% reduction in ulcer area versus a 29.9% reduction in the placebo arm, as measured 14 days after treatment began. In addition, 62.5% of patients treated with 2% Nu-3 saw a reduction in the microbiological load, versus 20% in the placebo.
Route of Administration: Topical
Minimum inhibitory concentrations of Nu-3 against Staphylococcus aureus cvcc 2248 is 4.4 mg/ml.
Name Type Language
NU-3
Code English
BISPHOSPHOCIN NU3
Brand Name English
BISPHOSPHOCIN NU-3
Brand Name English
BISPHOSPHOCIN (NU-3)
Brand Name English
3'-THYMIDYLIC ACID, MONOBUTYL ESTER, 5'-(BUTYL HYDROGEN PHOSPHATE)
Systematic Name English
1-(3,5-BIS-O-(BUTOXYHYDROXYPHOSPHINYL)-2-DEOXY-D-ERYTHRO-PENTOFURANOSYL)-5-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE
Common Name English
Code System Code Type Description
CAS
1630942-91-4
Created by admin on Sat Dec 16 01:06:12 GMT 2023 , Edited by admin on Sat Dec 16 01:06:12 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
CAS
403717-06-6
Created by admin on Sat Dec 16 01:06:12 GMT 2023 , Edited by admin on Sat Dec 16 01:06:12 GMT 2023
PRIMARY
PUBCHEM
10279357
Created by admin on Sat Dec 16 01:06:12 GMT 2023 , Edited by admin on Sat Dec 16 01:06:12 GMT 2023
PRIMARY
FDA UNII
8BK3483OW5
Created by admin on Sat Dec 16 01:06:12 GMT 2023 , Edited by admin on Sat Dec 16 01:06:12 GMT 2023
PRIMARY